Reply to E.L. Pollom et al, N. Ohri et al, A. Fiorentino et al, D.R. Wahl et al, N. Kim et al, J. Boda-Heggemann et al, S. Rana et al, N. Sanuki et al, J.R. Olsen et al, G.L. Smith et al, and A. Shinde et al
- PMID: 29945519
- DOI: 10.1200/JCO.2018.78.6418
Reply to E.L. Pollom et al, N. Ohri et al, A. Fiorentino et al, D.R. Wahl et al, N. Kim et al, J. Boda-Heggemann et al, S. Rana et al, N. Sanuki et al, J.R. Olsen et al, G.L. Smith et al, and A. Shinde et al
Comment on
-
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.J Clin Oncol. 2018 Feb 20;36(6):600-608. doi: 10.1200/JCO.2017.75.3228. Epub 2018 Jan 12. J Clin Oncol. 2018. PMID: 29328861
-
Comparing Modalities Using the National Cancer Database: Concerns With Rajyaguru et al.J Clin Oncol. 2018 Aug 20;36(24):2557. doi: 10.1200/JCO.2018.78.0403. Epub 2018 Jun 26. J Clin Oncol. 2018. PMID: 29945518 No abstract available.
-
Comparing Ablative Modalities for Hepatocellular Carcinoma: Cautions in Interpreting Big Data.J Clin Oncol. 2018 Aug 20;36(24):2565-2566. doi: 10.1200/JCO.2018.78.5428. Epub 2018 Jun 26. J Clin Oncol. 2018. PMID: 29945520 Free PMC article. No abstract available.
-
Cross-Modality Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy for Treatment of Hepatocellular Carcinoma: Limitations of the National Cancer Database.J Clin Oncol. 2018 Aug 20;36(24):2564-2565. doi: 10.1200/JCO.2018.78.2904. Epub 2018 Jun 26. J Clin Oncol. 2018. PMID: 29945521 No abstract available.
-
Are Head-to-Head Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy Really Necessary for Localized Hepatocellular Carcinoma?J Clin Oncol. 2018 Aug 20;36(24):2563-2564. doi: 10.1200/JCO.2018.78.2805. Epub 2018 Jun 26. J Clin Oncol. 2018. PMID: 29945522 No abstract available.
-
What Role Does Locally Ablative Stereotactic Body Radiotherapy Play Versus Radiofrequency Ablation in Localized Hepatocellular Carcinoma?J Clin Oncol. 2018 Aug 20;36(24):2560-2561. doi: 10.1200/JCO.2018.78.1740. Epub 2018 Jun 26. J Clin Oncol. 2018. PMID: 29945523 No abstract available.
-
Correspondence on Rajyaguru et al.J Clin Oncol. 2018 Aug 20;36(24):2561-2562. doi: 10.1200/JCO.2018.78.1542. Epub 2018 Jun 26. J Clin Oncol. 2018. PMID: 29945524 No abstract available.
-
Survival Analyses Are Flawed When Neglecting Barcelona Clinic Liver Cancer Staging.J Clin Oncol. 2018 Aug 20;36(24):2563. doi: 10.1200/JCO.2018.78.1575. Epub 2018 Jun 26. J Clin Oncol. 2018. PMID: 29945525 No abstract available.
-
Casual Causality: Does Radiofrequency Ablation Really Prolong Survival After Treatment of Localized Hepatocellular Carcinoma?J Clin Oncol. 2018 Aug 20;36(24):2559-2560. doi: 10.1200/JCO.2018.78.0882. Epub 2018 Jun 26. J Clin Oncol. 2018. PMID: 29945526 No abstract available.
-
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: Caution When Interpreting Observational Data.J Clin Oncol. 2018 Aug 20;36(24):2558. doi: 10.1200/JCO.2018.78.0122. Epub 2018 Jun 26. J Clin Oncol. 2018. PMID: 29945527 No abstract available.
-
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: No Way Out Without a Randomized Trial?J Clin Oncol. 2018 Aug 20;36(24):2558-2559. doi: 10.1200/JCO.2018.78.1005. Epub 2018 Jun 26. J Clin Oncol. 2018. PMID: 29945528 No abstract available.
-
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma: Does Radiation Dose Make a Difference?J Clin Oncol. 2018 Aug 20;36(24):2566-2567. doi: 10.1200/JCO.2018.78.6012. Epub 2018 Jun 26. J Clin Oncol. 2018. PMID: 29945529 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous